Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer
Molecular Therapy · 2025-11 · 33 (11) · 5415-5426
DOI: 10.1016/j.ymthe.2025.08.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy, 2025-11. Verfasst von Tracess B Smalley und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Oncogene Proteins, Viral, Uterine Cervical Neoplasms, Repressor Proteins, Papillomavirus Infections. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH National Institute of General Medical Sciences.
Abstract (Originalsprache)
Human Papilloma Virus (HPV)-related cancers are a global health burden, yet there are no targeted therapies available for chronically infected patients. The HPV protein E6 is essential for HPV-mediated tumorigenesis and immune evasion, making it an attractive target for antiviral drug development. In this study, we developed an E6-targeting Proteolysis Targeting Chimera (PROTAC) that inhibits the growth of HPV(+) tumors. To develop E6 antagonists, we generated a panel of nanobodies targeting E6 proteins derived from the oncogenic HPV16 subtype. The highest affinity E6 nanobody, A5, was fused to Von Hippel Lindau protein (VHL) to generate a PROTAC that degrades E6 (PROTAC E6 ). Mutational rescue experiments validated specific degradation via the CRL2 VHL E3 ligase. Intralesional administration of the PROTAC E6 using a clinically viable DNA vaccine reduced tumor burden in an immunocompetent mouse model of HPV(+) cancer. The inhibitory effect of the PROTAC E6 was abrogated by CD4 + and CD8 + T-cell depletion, indicating that the antitumor function of the PROTAC E6 relies in part on a host immune response. Overall, these results suggest that the targeted degradation of E6 inhibits its oncogenic function and stimulates a robust immune response against HPV(+) tumors, opening new opportunities for virus-specific therapies in the treatment of HPV-related cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33612, USA.
- Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, USA.
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Cancer Biology PhD Program, University of South Florida, Tampa, FL 33612, USA.
- Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA; Department of Molecular Medicine, Morsani College of Medicine, University of South Florida, Tampa, FL 33612, U…
- Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH National Institute of General Medical Sciences
- H. Lee Moffitt Cancer Center and Research Institute
- National Institutes of Health National Cancer Institute
- American Cancer Society Inc
- Centre for Incubation, Innovation, Research and Consultancy
- National Institutes of Health
Zitieren
APA
Smalley, T. B., Nicolaci, A. A., Tran, K. C., Lokhandwala, J., Obertopp, N., Matlack, J. K., Miner, R. E., Teng, M. N., Pilon-Thomas, S., & Binning, J. M. (2025). Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Molecular Therapy, 33(11), 5415-5426. https://doi.org/10.1016/j.ymthe.2025.08.033
Vancouver
Smalley TB, Nicolaci AA, Tran KC, Lokhandwala J, Obertopp N, Matlack JK, et al. Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer. Molecular Therapy. 2025;33(11):5415-5426. doi:10.1016/j.ymthe.2025.08.033
BibTeX
@article{Smalley2025,
author = {Smalley, Tracess B and Nicolaci, Angelo A and Tran, Kim C and Lokhandwala, Jameela and Obertopp, Nina and Matlack, Jenet K and Miner, Robert E and Teng, Michael N and Pilon-Thomas, Shari and Binning, Jennifer M},
title = {Targeted degradation of the HPV oncoprotein E6 reduces tumor burden in cervical cancer},
journal = {Molecular Therapy},
year = {2025},
volume = {33},
number = {11},
pages = {5415--5426},
doi = {10.1016/j.ymthe.2025.08.033}
}
EUVIMED